{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005357","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.729015+00:00","generated_at":"2026-06-18T22:34:03.329128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway","bullets":["Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.","Cash and cash equivalents fell to $143.2M at Dec 31, 2022 from $273.2M a year earlier.","Phase 3 pivotal program for COMP360 psilocybin in TRD ongoing; top-line data from trial COMP 005 expected summer 2024.","R&D expenses increased to $65.1M in FY2022 from $44.0M in FY2021, driven by clinical development.","FY2023 net cash used in operating activities guided at $85M-$110M; Q1 2023 at $24M-$32M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005357","json":"https://secwatch.observer/filing/0001628280-23-005357.json","markdown":"https://secwatch.observer/filing/0001628280-23-005357.md","text":"https://secwatch.observer/filing/0001628280-23-005357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/cmps-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:34:03.329128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35797a86741e1dc3e7b543cc346726b9b7834cce","claim":"COMPASS Pathways plc reported the three months ended December 31, 2022 results: net income $30.9 million, EPS $0.73 loss per share.","evidence_excerpt":"Net loss for the three months ended 31 December 2022 was $30.9 million, or $0.73 loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"$30.9 million"},{"label":"EPS","value":"$0.73 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"57c8e796d598ce348f7e4bbbeeff576c29d97278","claim":"COMPASS Pathways plc reported the year ended December 31, 2022 results: net income $91.5 million, EPS $2.16 loss per share.","evidence_excerpt":"Net loss for the year ended 31 December 2022 was $91.5 million, or $2.16 loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$91.5 million"},{"label":"EPS","value":"$2.16 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}